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Synthesis of pharmaceutically relevant 17-a-amino
steroids using an x-transaminase†
Nina Richter,ab Robert C. Simon,c Wolfgang Kroutil,bc John M. Wardd and
Helen C. Hailes*a
An eﬃcient and sustainable biocatalytic route for the synthesis of
important 17-a-amino steroids has been developed using an x-
transaminase variant from Arthrobacter sp. Optimisation of the
reaction conditions facilitated the synthesis of these valuable syn-
thons on a preparative scale, aﬀording excellent isolated yields and
stereocontrol.
Steroids are a large and diverse class of secondary metabolites,
essential for the control of a variety of biological processes. Based
on this key role inmetabolism, steroids and their derivatives often
exhibit biological activity and therefore have enormous potential
as pharmaceuticals.1 Indeed, approximately 300 steroidal drugs
have been placed on the market since 1950 with cortisone as one
prominent example.1,2 Moreover, among the 200 top-selling drugs
in 2010 13% were steroids and derivatives thereof.3 17-Amino
steroids (1) (Fig. 1) have proven to be particularly interesting non-
natural steroids that are used as intermediates in the synthesis
of biologically active steroidal derivatives. For example the
17b-arylsulfonamide derivative 2 has recently been highlighted
as a potent inhibitor of steroid sulfatase, a target in the treatment
of breast cancer.4–7 Moreover, a number of 17b-aminoestrogens
were identified to have a prolonged anticoagulant effect in
rodents.8 In both examples the amine functionality, and deriva-
tives thereof, attached to the C-17 position of the steroid is
presumed to be crucial for the biological activity.
In general, the 17b-amino steroid motif is accessible by a
classical two-step method, via reductive amination and
deprotection, and consequently studies have focussed on deri-
vatives of the b-epimer.6,7 Although the synthesis of the
17a-amino steroid is less eﬃcient, requiring a three-step syn-
thetic route with a low yielding reduction reaction, the a-epimer
derivative 3 (Fig. 1) was also found to be a potent sulfatase
inhibitor.6,8 As a consequence of the poor accessibility of the
a-epimer the potential of further derivatives has to the best of
our knowledge not been investigated to date. Therefore, the
development of an eﬃcient method for the synthesis of the
a-epimer would be highly desirable. Here we present a novel
route to access 17-a-amino steroids by applying the use of an
o-transaminase (o-TAm). o-TAms are continuing to attract
significant attention for use in asymmetric synthesis for the
generation of both (S)- and (R)-chiral amines.9–19 Moreover,
biocatalytic strategies employing o-TAms have been used for
the synthesis of pharmaceutically relevant compounds,20–27
even leading to the development of an industrial process.28
In initial studies our aim was to use two previously reported
o-TAms, Vibrio fluvialis (Vf-TAm),10 and Chromobacterium vio-
laceum DSM30191 (CV-TAm),16 and a particularly interesting
o-TAm variant described, from Arthrobacter sp. (ArRMut11).28
CV-TAm has previously been reported for the transamination of
a wide range of ketones including more sterically challenging
substrates such as 1,3-dihydroxy-1-phenylpropan-2-one,16,25
Fig. 1 Steroid core structure 1 with amino group at C-17, and 17b- and
17a-sulfonamide derivatives 2 and 3, respectively.
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while Vf-TAm has been used with in general smaller sub-
strates.11,14 The o-TAm ArRMut11 variant was evolved by Savile
and co-workers over 11 rounds of mutation, to catalyse the
amination of sterically demanding 1,3-ketoamides to generate
the (R)-aminoamide functionality present in sitagliptin.28 An
additional feature of this variant is its tolerance towards high
co-solvent concentrations and 2-propylamine, facilitating the
use of this low cost amine donor to shift the equilibrium
towards the product.11,17,28–31 The variant ArRMut11 has also
been successfully used for the transamination of tetralone
and chromone bicyclic compounds.29,30 For the generation of
17a-amino steroids TAms are required with good co-solvent
tolerance, due to the limited aqueous solubilities of the sub-
strates, and ability to accept the large tetracyclic steroidal ring
system. Here we describe the use of the three o-TAms and
optimisation of the reaction conditions using ArRMut11 as a
novel route to 17-a-amino steroids.
To evaluate the potential of the selected o-TAms in the asym-
metric amination of steroid precursors, the truncated analogue 4
and steroid 5 (10 mM) were initially screened against the three
o-TAms using either (R) or (S)-a-methylbenzylamine as the amine
donor, depending on the selectivity of the o-TAm used, and
acetophenone production was monitored by HPLC analysis.
Only for ArRMut11 were conversions45% detected, so this
o-TAm was used in further experiments with 4–8 (10 mM) using
isopropylamine as a low cost donor (Scheme 1) and 20% of
either 1,2-dimethoxyethane (DME) (4 and 5) or dimethylsulf-
oxide (DMSO) (6–8) as co-solvent. LC-MS analysis indicated that
5–7 were good substrates for the o-TAm. Although substrates 4
and 8 seemed to be accepted by the enzyme and m/z peaks
corresponding to the product were detected by LC-MS, it was
not possible to isolate a single product. This was not surprising
due to the two ketone moieties in 4 complicating product
analysis, and a,b-unsaturated enones in both 4 and 8 which
can form conjugated enamines in the presence of amines.
Compounds 4 and 8 were therefore not explored further.
The reaction conditions were then optimised in order to
maximise reaction rates and conversion yields using trans-
dehydroandrosterone (5) as a model substrate (1 mL, 10 mM).
Parameters including the employment of co-solvents, to increase the
substrate solubility, as well as the amount of amine donor
2-propylamine, to maximise the conversion rate were explored.
DMSO is frequently used as a co-solvent in biocatalysis, but the
substrates were not fully soluble in mixtures of DMSO–water. DME
and dimethylformamide (DMF) have recently been applied success-
fully as co-solvents in o-TAm reactions so their potential here was
investigated.32 Both DME and DMF enhanced the solubility of the
substrates in mixed aqueous systems giving rise to clear rather than
cloudy solutions, whereas substrates exhibited the best solubilities
in water–DMF mixtures. Comparative studies using 25% of DME or
DMF as co-solvents led to similar conversions (B60%) after a
reaction time of 6 days (Fig. S1a, ESI†), however since higher
reaction rates were observed with DMF it was selected as a
co-solvent for all further experiments. The impact of different
DMF concentrations (25–50%) on reaction rate and conversion were
investigated as well. While conversions after 6 days were again
rather similar (64–68%) the fastest reaction rate and highest con-
version (68%) were reached using 35% of DMF as an optimal
co-solvent concentration.
The concentration of the amine donor 2-propylamine was then
investigated using 20-, 50- and 100-fold molar excesses to shift the
equilibrium of theo-TAm reaction towards the aminated steroid. The
conversion of 5 to 17-amino-3b-hydroxyandrost-5-ene was improved
from 40% after 6 days using a 20-fold excess of 2-propylamine to 81%
after 5 days using a 100-fold excess (Fig. S1b, ESI†). The reaction
profile for the biotransformation using the optimised conditions
(35%DMF and 100-foldmolar excess of 2-propylamine) over a period
of 6 days is shown in Fig. 2. The data indicated that the reaction
conditions were well tolerated by o-TAm ArRMut11.
As a consequence these optimised conditions were used
for the asymmetric amination of steroids 6 and 7 (1 mL,
10 mM). These were successfully transformed to the corre-
sponding 17-amino steroids with excellent conversions, yielding
Scheme 1 TAm reaction using ArRMut11 and substrates 4–8.
Fig. 2 Reaction profile of the asymmetric amination of 5 (1 mL, 10 mM)
using the optimised conditions: o-TAm ArRMut11, 35% v/v DMF–water and
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17-amino-1,3,5(10)-estratrien-3-ol from 6 in 68% yield and 17-amino-
5a-androstan-3b-ol from 7 in 71% yield (Table S1, ESI†). The
transamination of 5–7 was then performed on preparative scale
(50mg substrate; 20mL, 10mM). Reactions were stopped after three
days and the conversion and stereoselectivity of the reaction deter-
mined by GC and NMR analysis. Interestingly, on a preparative scale
all biotransformations showed enhanced conversions compared
to the previous results despite a shorter reaction time (Table 1 cf.
Table S1, ESI†): however for the synthesis of 5a this could be ascribed
to the slightly higher amounts of enzyme used. In particular, the
amination of steroid 6was improved 1.4 fold, giving amine 6awith a
conversion of 96%. Amines 5a and 7a were also produced with
excellent conversions of 88% and 90%, respectively. To establish
the stereoselectivities reaction products were purified by flash silica
chromatography, and isolated in yields of 83% (5a), 85% (6a)
and 89% (7a).
Assignment of the absolute configuration of the products was
carried out by comparing the previously reported NMR spectro-
scopic data to that of 6a and using 1H NMR NOESY experiments
(between 17-H and the methyl group at C-13).8 These indicated
that the 17-a-epimer (anti) was formed with full stereocontrol in
all three cases. The newly formed chiral amine moiety has an
(R)-configuration, in agreement with previous stereoselectivities
reported using the (R)-selective o-TAm ArRMut11. This biocata-
lytic approach gives the 17-a-amino steroids in one step, starting
from the corresponding carbonyl compound, in excellent iso-
lated yields of 83–89%, and highlights the tolerance of the
o-TAm ArRMut11 to such sterically challenging substrates.
Compared to the classical chemical synthesis of 6a reported
not only was the number of synthetic steps reduced from three to
one, but also the overall yield was improved 9-fold.8
In summary, a highly stereoselective, eﬃcient and sustainable
biocatalytic route, facilitating access to a variety of highly desirable
17-a-amino steroids has been developed. After optimisation of the
reaction parameters the 17-a-amino steroids were synthesised in high
isolated yields of 83–89% via a one-step procedure on a preparative
scale. This novel biocatalytic methodology enables access to the
a-epimer of key intermediates in the synthesis of biologically active
steroidal derivatives. Moreover, the described method represents the
shortest routes towards 17-a-amino steroids published to date.
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Syn : anti ratioa
(major isomer)
5 88 83 1 : 99(17-a-R)
6 96 85 1 : 99(17-a-R)
7 90 89 1 : 99(17-a-R)
a Determined by GC analysis and 1H NMR spectroscopy: no b-epimer
detected, ratios reflect detection limit (GC).
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